Monopar Therapeutics MNPR Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $52.54M+32.3% | $61.83M+35.0% | $127.68M+2,021% | $39.5M+545% | $39.71M+409% | ||
| $52.37M+32.5% | $60.88M+33.7% | $127.5M+2,100% | $39.33M+472% | $39.51M+381% | ||
| $137.74M+150% | $140.46M+133% | $144.09M+2,274% | $53.75M+649% | $55.08M+518% | ||
| $239.88K+2,535% | $254.92K— | $106.67K— | $118.17K— | $9.1K— | ||
| $84.95M— | $78.57M— | $16M— | —— | —— | ||
| $137.98M+150% | $140.72M+133% | $144.2M+2,276% | $53.87M+650% | $55.09M+518% | ||
| $2.46M+64.7% | $2.74M+21.3% | $2.57M+129% | $1.58M+45.4% | $1.49M+4.0% | ||
| $98.86K+1,098% | $90.57K— | $31.36K— | $33.37K— | $8.25K— | ||
| $2.46M— | —— | —— | —— | —— | ||
| $131.57K— | $154.92K— | $70.88K— | $80.37K— | $0— | ||
| $230.43K+2,692% | $245.49K— | $102.24K— | $113.74K— | $8.25K— | ||
| $2.59M+73.6% | $2.89M-45.0% | $2.64M+135% | $1.66M+52.7% | $1.49M+4.0% | ||
| $6.7K+9.6% | $6.69K+9.7% | $6.66K+89.0% | $6.13K-65.2% | $6.12K-65.0% | ||
| $228.69M+73.2% | $227.2M+73.7% | $225.85M+223% | $132.99M+91.0% | $132.03M+90.5% | ||
| -$93.4M-19.1% | -$89.51M-18.1% | -$84.31M-30.0% | -$80.87M-27.2% | -$78.42M-26.8% | ||
| $98.52K+552% | $131.39K+265% | $11.7K+206% | $77.58K+839% | -$21.78K-615% | ||
| $135.39M+153% | $137.83M+150% | $141.56M+2,762% | $52.2M+757% | $53.59M+617% | ||
| $137.98M+150% | $140.72M+133% | $144.2M+2,276% | $53.87M+650% | $55.09M+518% | ||
| —— | —— | —— | —— | —— | ||
| $52.37M+32.5% | $60.88M+33.7% | $127.5M+2,100% | $39.33M+472% | $39.51M+381% | ||
| $250.9K-52.1% | $63.75K-19.2% | $414.83K+737% | $497.29K+715% | $523.56K+340% | ||
| $239.88K+2,535% | $254.92K— | $106.67K— | $118.17K— | $9.1K— | ||
| $84.95M— | $78.57M— | $16M— | —— | —— | ||
| $239.88K+2,535% | $254.92K— | $106.67K— | $118.17K— | $9.1K— | ||
| $239.88K+2,535% | $254.92K— | $106.67K— | $118.17K— | $9.1K— | ||
| $2.46M+64.7% | $2.74M+21.3% | $2.57M+129% | $1.58M+45.4% | $1.49M+4.0% | ||
| $230.43K— | $245.49K— | —— | —— | —— | ||
| $228.69M+73.2% | $227.2M+73.7% | $225.85M+223% | $132.99M+91.0% | $132.03M+90.5% | ||
| $6.7K+9.6% | $6.69K+9.7% | $6.66K+89.0% | $6.13K-65.2% | $6.12K-65.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Monopar Therapeutics's total assets?
- Monopar Therapeutics (MNPR) holds $138.0M in total assets, up 150.5% year over year.
- How much debt does Monopar Therapeutics have?
- Monopar Therapeutics carries $230.4K in total debt against $135.4M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Monopar Therapeutics have?
- Monopar Therapeutics holds $52.5M in cash and equivalents.
- Can Monopar Therapeutics cover its short-term obligations?
- Its current ratio is 56.04 — current assets exceed current liabilities.
- Where does Monopar Therapeutics's balance sheet data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.